Related Experiment Video
Updated: Aug 5, 2026
05:08
Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid
Published on: September 20, 2017
Tailored Drug Release with Improved Solubility via Spray Drying and Functional Ready-to-Fill Capsules
Kristina Vlahovic1, Lilla Dorottya Kóró1, Bence Dávid Tóth1
1Department of Pharmaceutics, Semmelweis University, Hőgyes Endre Street 7, 1092 Budapest, Hungary.
Pharmaceutics
|July 28, 2026
Summary
Spray drying with Eudragit E PO and tartaric acid significantly enhances albendazole solubility. A colon-delivery formulation ensures effective drug release at the site of action, improving therapeutic potential.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Albendazole (ABZ) exhibits poor solubility in alkaline environments, limiting its therapeutic efficacy.
- Spray drying is a key technique for enhancing the solubility of poorly soluble drugs.
- Eudragit E PO (EudE) and organic acids are known to improve solubility of weakly basic drugs.
Purpose of the Study:
- To enhance albendazole (ABZ) solubility using spray drying with Eudragit E PO (EudE) and tartaric acid (TA).
- To develop a colon-delivery formulation for ABZ with improved solubility at pH 7.2.
Main Methods:
- Development of spray-dried formulations of ABZ-TA-EudE.
- Selection of the optimal formulation based on solubility.
- Loading the selected formulation into EUDRACAP® colon for colon-delivery.
- Evaluation of physicochemical characteristics and in vitro drug release.
Main Results:
- The ternary ABZ-TA-EudE formulation demonstrated significantly enhanced ABZ solubility.
- Spray-dried formulations exhibited improved physicochemical properties and in vitro drug release compared to physical mixtures.
- EUDRACAP® colon successfully delivered the ABZ formulation, showing enhanced release at pH 7.2.
Conclusions:
- Tartaric acid and Eudragit E PO synergistically enhance the solubility of albendazole in spray-dried formulations.
- EUDRACAP® colon is an effective system for colon-specific delivery of ABZ, ensuring release at the target site.
- This approach improves ABZ solubility and release at its site of action, potentially increasing therapeutic efficacy.
Related Concept Videos
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:16Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...